Skip to content

Tolerance and Acceptability Evaluation AYMES ActaGain

Tolerance and Acceptability Evaluation AYMES ActaGain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04703881
Enrollment
17
Registered
2021-01-11
Start date
2020-07-01
Completion date
2020-10-01
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Brief summary

To evaluate tolerance and acceptability of 'AYMES ActaGain' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Detailed description

To evaluate tolerance and acceptability of 'AYMES ActaGain' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference, convenience etc. To obtain data to support an ACBS submissions for 'AYMES ActaGain' (to allow for prescription in the community at NHS expense).

Interventions

DIETARY_SUPPLEMENTAYMES ActaGain

AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.

Sponsors

Aymes International Limited
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female patients. * ≥ 18 years of age. * Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks. * Patient is able and willing to provide written informed consent.

Exclusion criteria

* Patients with medical or dietary contraindication to any feed ingredients. * Patients requiring sole enteral tube feeding or parenteral nutrition. * Patients with chronic renal disease requiring dialysis. * Patients with liver failure. * Patients for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements. * Patients assessed by a Speech and Language Therapist who require thickened fluids. * Participation in any other studies that may interfere with this study.

Design outcomes

Primary

MeasureTime frameDescription
Gastro-Intestinal Tolerance when consuming AYMES ActaGain30 daysTo assess gastro-intestinal tolerance of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number of any GI complaints via a daily diary.

Secondary

MeasureTime frameDescription
Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire30 daysTo assess the acceptability of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.
Compliance30 daysTo assess the acceptability of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. A daily compliance diary will be kept detailing compliance to prescription versus prescribed amount.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026